400-859-2883
Your location:Home >News center >Industry News

Industry News

11-182023

List of FDA Approved PEGylated Drugs Up t…

History of PEGylated drugs, list of FDA approved PEGylated drugs, advantages and challenges of PEGylation.

List of FDA Approved PEGylated Drugs Up to 2025
05-232025

AACR 2025 Highlights: Dual Payload & …

Discover key highlights from the 2025 AACR Annual Meeting, where cutting-edge ADC innovations—from dual-payloads to immunotherapy combos—are reshaping cancer treatment.

AACR 2025 Highlights: Dual Payload & Bispecific ADCs
05-142025

N-Benzylhydroxylamine Hydrochloride (CAS …

N-Benzylhydroxylamine hydrochloride (CAS 29601-98-7) is a versatile organic compound featuring a unique nitrogen–oxygen (N–O) functional group. This structural characteristic endows it with…

N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7): A Promising Compound in Drug Development
04-172025

18 Approved ADCs Worldwide: The Ultimate …

As of 2025, a total of 18 ADC drugs have been approved globally.

18 Approved ADCs Worldwide: The Ultimate Guide (Updated 2025)
03-302025

The Next Generation of Obesity Treatments…

Recently, Nature published an in-depth report on the upcoming wave of next-generation weight-loss therapies.

The Next Generation of Obesity Treatments
02-212025

Semaglutide & Tirzepatide: Leading GL…

Eli Lilly and Novo Nordisk are the undisputed leaders in the market for GLP-1 drugs, a class of medications used to treat both diabetes and obesity.

Semaglutide & Tirzepatide: Leading GLP-1 Drug Sales in 2024
02-072025

Promising MASH Therapies Under Develpment…

Currently, over 500 MASH therapies are in development worldwide, with 5 drugs having advanced to Phase 3 clinical trials.

Promising MASH Therapies Under Develpment
01-222025

FDA Approvals 2024 & Potential First-…

In this article, we will review the key highlights of FDA-approved therapies in 2024 and explore potential first-in-class therapies expected to gain approval in 2025.

FDA Approvals 2024 & Potential First-in-Class Therapies to Watch in 2025
12-242024

Overview: ADC Drugs Expected to Receive F…

The U.S. Food and Drug Administration (FDA) did not approve any new ADCs in 2023 or 2024. However, with ongoing advancements in technology and clinical research, multiple ADC drugs are antici…

Overview: ADC Drugs Expected to Receive FDA Approval in 2025
12-122024

ROR1: A Promising Target for Cancer Thera…

Recent clinical trial data presented at the 66th American Society of Hematology (ASH) Annual Meeting, especially regarding zilovertamab vedotin and CS5001, has attracted considerable attentio…

ROR1: A Promising Target for Cancer Therapy